These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29695616)
21. Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults. Li GF; Zheng QS; Yu Y; Zhong W; Zhou HH; Qiu F; Wang G; Yu G; Derendorf H Clin Pharmacokinet; 2019 Jul; 58(7):927-941. PubMed ID: 30767128 [TBL] [Abstract][Full Text] [Related]
22. Scaling Factors for Clearance in Adult Liver Cirrhosis. El-Khateeb E; Achour B; Scotcher D; Al-Majdoub ZM; Athwal V; Barber J; Rostami-Hodjegan A Drug Metab Dispos; 2020 Dec; 48(12):1271-1282. PubMed ID: 32978222 [TBL] [Abstract][Full Text] [Related]
23. Characterisation of the DNA repair enzyme for O(6)-methylguanine in cirrhosis. Collier JD; Bassendine MF; Burt AD; Major GN J Hepatol; 1996 Aug; 25(2):158-65. PubMed ID: 8878776 [TBL] [Abstract][Full Text] [Related]
24. Comparative Intra-Subject Analysis of Gene Expression and Protein Abundance of Major and Minor Drug Metabolizing Enzymes in Healthy Human Jejunum and Liver. Wenzel C; Lapczuk-Romanska J; Malinowski D; Ostrowski M; Drozdzik M; Oswald S Clin Pharmacol Ther; 2024 Feb; 115(2):221-230. PubMed ID: 37739780 [TBL] [Abstract][Full Text] [Related]
25. A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Terada T; Terasaki S; Nakanuma Y Cancer; 1993 Sep; 72(5):1551-6. PubMed ID: 8394196 [TBL] [Abstract][Full Text] [Related]
26. Reduced hepatic glycogen stores in patients with liver cirrhosis. Krähenbühl L; Lang C; Lüdes S; Seiler C; Schäfer M; Zimmermann A; Krähenbühl S Liver Int; 2003 Apr; 23(2):101-9. PubMed ID: 12654132 [TBL] [Abstract][Full Text] [Related]
27. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. Serra MA; Escudero A; Rodríguez F; del Olmo JA; Rodrigo JM J Clin Gastroenterol; 2003 Feb; 36(2):170-4. PubMed ID: 12544203 [TBL] [Abstract][Full Text] [Related]
28. Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. Khatri R; Fallon JK; Rementer RJB; Kulick NT; Lee CR; Smith PC J Pharmacol Toxicol Methods; 2019; 98():106590. PubMed ID: 31158457 [TBL] [Abstract][Full Text] [Related]
29. Inflammatory status in human hepatic cirrhosis. Martínez-Esparza M; Tristán-Manzano M; Ruiz-Alcaraz AJ; García-Peñarrubia P World J Gastroenterol; 2015 Nov; 21(41):11522-41. PubMed ID: 26556984 [TBL] [Abstract][Full Text] [Related]
30. Aldehyde content of collagen from alcoholic cirrhotic and noncirrhotic human livers. Feinman L; Fecher R; Lue SL; Lieber CS Exp Mol Pathol; 1979 Apr; 30(2):271-8. PubMed ID: 421872 [No Abstract] [Full Text] [Related]
31. Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women. Lorenzo A; Auguet T; Vidal F; Broch M; Olona M; Gutiérrez C; López-Dupla M; Sirvent JJ; Quer JC; Santos M; Richart C Drug Alcohol Depend; 2006 Sep; 84(2):195-200. PubMed ID: 16600530 [TBL] [Abstract][Full Text] [Related]
32. Histological demonstration and frequency of intrahepatocytic copper in patients suffering from alcoholic liver disease. Berresford PA; Sunter JP; Harrison V; Lesna M Histopathology; 1980 Nov; 4(6):637-43. PubMed ID: 7439891 [TBL] [Abstract][Full Text] [Related]
33. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. Furlan V; Demirdjian S; Bourdon O; Magdalou J; Taburet AM J Pharmacol Exp Ther; 1999 May; 289(2):1169-75. PubMed ID: 10215701 [TBL] [Abstract][Full Text] [Related]
34. Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. Khan AJ; Husain Q; Choudhuri G; Parmar D Drug Alcohol Depend; 2010 Jun; 109(1-3):190-7. PubMed ID: 20171022 [TBL] [Abstract][Full Text] [Related]
37. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States. Sharma S; Suresh Ahire D; Prasad B J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S17-S35. PubMed ID: 33205430 [TBL] [Abstract][Full Text] [Related]
38. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113 [TBL] [Abstract][Full Text] [Related]
39. Changes in Characteristics of Patients with Liver Cirrhosis Visiting a Tertiary Hospital over 15 Years: a Retrospective Multi-Center Study in Korea. Jang WY; Chung WJ; Jang BK; Hwang JS; Lee HJ; Hwang MJ; Kweon YO; Tak WY; Park SY; Lee SH; Lee CH; Kim BS; Kim SH; Suh JI; Park JG J Korean Med Sci; 2020 Jul; 35(29):e233. PubMed ID: 32715667 [TBL] [Abstract][Full Text] [Related]